Log in

NASDAQ:CLLS - Cellectis Stock Price, Forecast & News

$8.60
-0.12 (-1.38 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
$8.18
Now: $8.60
$9.00
50-Day Range
$7.81
MA: $14.16
$18.82
52-Week Range
$7.32
Now: $8.60
$20.84
Volume99,191 shs
Average Volume176,587 shs
Market Capitalization$365.07 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. It is also developing UCARTCLL1 to treat AML; ALLO-819 for treating AML; UCARTCS1 for the treatment of multiple myeloma (MM); and ALLO-715 to treat MM. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; Cornell University; Dana Farber Cancer Institute; and H. Lee Moffitt Cancer Center. Cellectis S.A. was founded in 1999 and is based in Paris, France.
Read More
Cellectis logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLLS
CUSIPN/A
Phone33-1-81-69-16-00

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.99 million
Book Value$8.37 per share

Profitability

Net Income$-102,090,000.00
Net Margins-444.90%

Miscellaneous

Employees161
Market Cap$365.07 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.


Cellectis (NASDAQ:CLLS) Frequently Asked Questions

How has Cellectis' stock been impacted by COVID-19 (Coronavirus)?

Cellectis' stock was trading at $11.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CLLS stock has decreased by 24.8% and is now trading at $8.60. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cellectis?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cellectis.

When is Cellectis' next earnings date?

Cellectis is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Cellectis.

How were Cellectis' earnings last quarter?

Cellectis SA (NASDAQ:CLLS) posted its quarterly earnings results on Wednesday, March, 4th. The biotechnology company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by $0.04. The biotechnology company earned $6.34 million during the quarter, compared to the consensus estimate of $3.87 million. Cellectis had a negative net margin of 444.90% and a negative return on equity of 25.89%. View Cellectis' earnings history.

What price target have analysts set for CLLS?

5 brokers have issued twelve-month price targets for Cellectis' stock. Their forecasts range from $11.00 to $73.00. On average, they expect Cellectis' stock price to reach $34.75 in the next twelve months. This suggests a possible upside of 304.1% from the stock's current price. View analysts' price targets for Cellectis.

Has Cellectis been receiving favorable news coverage?

Headlines about CLLS stock have trended extremely negative this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cellectis earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutCellectis.

Are investors shorting Cellectis?

Cellectis saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 338,500 shares, an increase of 5.7% from the February 27th total of 320,200 shares. Based on an average daily volume of 129,700 shares, the short-interest ratio is presently 2.6 days. Currently, 0.8% of the company's shares are short sold. View Cellectis' Current Options Chain.

Who are some of Cellectis' key competitors?

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Calyxt (CLXT), NVIDIA (NVDA), Gilead Sciences (GILD), Editas Medicine (EDIT), Advanced Micro Devices (AMD), Micron Technology (MU), Crispr Therapeutics (CRSP), Exelixis (EXEL), Intellia Therapeutics (NTLA) and Sangamo Therapeutics (SGMO).

Who are Cellectis' key executives?

Cellectis' management team includes the following people:
  • Dr. André Choulika, Co-Founder, Chairman & CEO (Age 54)
  • Dr. David J. D. Sourdive, Co-Founder, Deputy CEO, Exec. VP of Technical Operations & Director (Age 52)
  • Mr. Eric Dutang, Chief Financial Officer (Age 45)
  • Ms. Elsy Boglioli, Chief Operating Officer (Age 37)
  • Mr. Jean Charles Epinat, Chief Technological Officer

When did Cellectis IPO?

(CLLS) raised $129 million in an IPO on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Who are Cellectis' major shareholders?

Cellectis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (7.50%), ARK Investment Management LLC (3.16%), Nikko Asset Management Americas Inc. (3.01%), Sumitomo Mitsui Trust Holdings Inc. (3.01%), Capital International Investors (2.39%) and Credit Suisse AG (1.09%).

Which major investors are selling Cellectis stock?

CLLS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Point72 Asset Management L.P., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., UBS Group AG, Cubist Systematic Strategies LLC, Victory Capital Management Inc., and Eqis Capital Management Inc..

Which major investors are buying Cellectis stock?

CLLS stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Rhenman & Partners Asset Management AB, ARK Investment Management LLC, Capital Asset Advisory Services LLC, Geode Capital Management LLC, Atria Investments LLC, OneAscent Financial Services LLC, and Granite Point Capital Management L.P..

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $8.60.

How big of a company is Cellectis?

Cellectis has a market capitalization of $365.07 million and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Cellectis employs 161 workers across the globe. View additional information about Cellectis.

What is Cellectis' official website?

The official website for Cellectis is http://www.cellectis.com/.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]


MarketBeat Community Rating for Cellectis (NASDAQ CLLS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  368 (Vote Outperform)
Underperform Votes:  254 (Vote Underperform)
Total Votes:  622
MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote "Outperform" if you believe CLLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: What are retained earnings?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel